FDA could gain new powers next year

11/3/2006 | RPM Report (free registration), The

The FDA could gain several new powers when Congress examines drug safety reforms next year, including greater authority over prescription labels. Other changes could include requiring risk management plans for new drugs, establishing post-market PDUFA goals for safety issues, and clinical trial registration for Phase II, III and IV studies.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD